Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1993-7-30
|
pubmed:abstractText |
The effects of 3-O-dodecylcarbomethylascorbic acid (3-O-DAsA), 3-O-ethylascorbic acid (3-O-EAsA) and 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ) on 2-amino-6-methyldipyrido[1,2-a:3',2'-d]-imidazole (Glu-P-1)-induced mutagenesis and hepatocarcinogenesis were examined. In a Salmonella assay, addition of 2.5 to 20.0 mg of HTHQ to Salmonella TA 98 in the presence of S-9 mixture dose-dependently inhibited Glu-P-1-induced mutagenesis. The highest dose showed a 99% reduction in revertants. 3-O-DAsA and 3-O-EAsA were without effect. In an animal study using the medium-term bioassay system for the detection of hepatocarcinogens or hepatopromoters in F344 male rats, treatment with Glu-P-1 alone was associated with a significant increase in the number and area of GST-P-positive foci (47.5 +/- 8.9 and 11.1 +/- 4.7, respectively). Combined treatment with 1.0% HTHQ significantly reduced the number and area of GST-P-positive foci (to 8.1 +/- 2.1 and 0.6 +/- 0.2) while 3-O-DAsA exerted marginal inhibition and 3-O-EAsA had no effect. On the other hand, all three of these compounds slightly enhanced the numbers and areas of foci when given alone. The results indicate that HTHQ is a potent chemopreventer of Glu-P-1-induced hepatocarcinogenesis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-amino-6-methyldipyrido(1,2-a-3',2'...,
http://linkedlifedata.com/resource/pubmed/chemical/Anticarcinogenic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antimutagenic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antioxidants,
http://linkedlifedata.com/resource/pubmed/chemical/Ascorbic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroquinones,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Mutagens
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0910-5050
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
84
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
481-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8320163-Animals,
pubmed-meshheading:8320163-Anticarcinogenic Agents,
pubmed-meshheading:8320163-Antimutagenic Agents,
pubmed-meshheading:8320163-Antioxidants,
pubmed-meshheading:8320163-Ascorbic Acid,
pubmed-meshheading:8320163-Body Weight,
pubmed-meshheading:8320163-Hydroquinones,
pubmed-meshheading:8320163-Imidazoles,
pubmed-meshheading:8320163-Liver Neoplasms, Experimental,
pubmed-meshheading:8320163-Male,
pubmed-meshheading:8320163-Mutagens,
pubmed-meshheading:8320163-Rats,
pubmed-meshheading:8320163-Rats, Inbred F344
|
pubmed:year |
1993
|
pubmed:articleTitle |
Strong inhibition of 2-amino-6-methyldipyrido[1,2-a:3',2'-d] imidazole-induced mutagenesis and hepatocarcinogenesis by 1-O-hexyl-2,3,5-trimethylhydroquinone.
|
pubmed:affiliation |
First Department of Pathology, Nagoya City University, Medical School.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|